GlassScriptPhysician profile
Asisat A Ope
NPI 1992186928
$4,873.26
in general payments reported to CMS, 2019-2025
27 companies · $18.13 in 2025
The $18.13 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $266 · 2021: $186 · 2022: $45.63 · 2023: $27.85 · 2024: $3,714 · 2025: $18.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,074 · Consulting Fee: $1,000 · Food and Beverage: $686.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,074.30 |
| Consulting Fee | $1,000.00 |
| Food and Beverage | $685.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $2,680.30 | 2024 | |
| Pfizer INC. | $1,145.71 | 2019-2024 | |
| Novo Nordisk INC | $197.65 | 2019-2021 | |
| Abbvie INC. | $113.52 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $82.65 | 2019-2020 | |
| Antares Pharma, INC. | $53.16 | 2021 | |
| Amarin Pharma, INC. | $50.77 | 2020 | |
| Sanofi-Aventis U.S. LLC | $49.36 | 2019 | |
| Amgen INC. | $46.45 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $46.30 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $45.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.45 | 2019 | |
| Optinose US, INC. | $42.49 | 2019-2020 | |
| Sanofi Pasteur INC. | $36.65 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.32 | 2019-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.28 | 2019-2020 | |
| Allergan, INC. | $28.14 | 2020 | |
| Hologic Sales and Service, LLC | $23.44 | 2021 | |
| Glaxosmithkline, LLC. | $23.19 | 2019 | |
| Dynavax Technologies Corporation | $18.99 | 2019 | |
| Ibsa Pharma INC. | $18.34 | 2019 | |
| Genentech USA, INC. | $16.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $16.72 | 2021 | |
| Shire North American Group INC | $15.14 | 2019 | |
| Eisai INC. | $14.94 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asisat Ope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.